Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
In the era of personalized medicine, epidermal growth factor receptor (EGFR) inhibition with tyrosine kinase inhibitor (TKI) has been a mainstay of treatment for non-small cell lung cancer (NSCLC) patients with an EGFR mutation. Acquired resistance, especially substitution of methionine for threoni...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2014-06-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2075-4426/4/3/297 |